<DOC>
	<DOCNO>NCT02995746</DOCNO>
	<brief_summary>This study seek evaluate effect intravitreal 0.7mg dexamethasone implant central macular thickness visual acuity patient persistent macular edema par plana vitrectomy epiretinal membrane .</brief_summary>
	<brief_title>Intravitreal Dexamethasone Implant Persistent Macular Thickening Edema After Vitrectomy Epiretinal Membrane</brief_title>
	<detailed_description>Macular edema relatively common occurrence par plana vitrectomy . Kim et al describe 47 % eye undergo vitrectomy epiretinal membrane , macular hole , vitreous hemorrhage evidence macular thicken optical coherence tomography scan.1 Post-vitrectomy macular edema limit potential visual acuity gain removal symptomatic epiretinal membrane . Typical treatment post-operative macular edema consist topical non-steroidal anti-inflammatory drug ( NSAIDs ) topical corticosteroid ; however , still resistant case refractory macular thickening . The dexamethasone intravitreal implant ( Ozurdex ; Allergan , Irvine , CA ) currently FDA-approved treatment posterior uveitis well macular edema secondary retinal vein occlusion diabetic retinopathy . Furino et al report retrospective series describe single injection 0.7mg dexamethasone intravitreal implant result substantial increase best-corrected visual acuity ( BCVA ) decrease central macular thickness ( CMT ) spectral-domain optical coherence tomography ( SD-OCT ) 8 patient persistent macular thicken par plana vitrectomy epiretinal membrane . There prospective study evaluate efficacy pharmacologic agent set . As , purpose study prospectively evaluate effect intravitreal 0.7mg dexamethasone implant CMT BCVA patient persistent macular edema par plana vitrectomy epiretinal membrane . The result study help delineate whether intravitreal dexamethasone implant efficacy improve CMT and/or visual acuity patient refractory macular thicken par plana vitrectomy epiretinal membrane .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Epiretinal Membrane</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patient Wills Eye Institute Retina service , include MidAtlantic Retina office 2 . Volunteer patient age 18 year old 3 . Healthy enough participate study 4 . Willing able consent participation study 5 . History par plan vitrectomy symptomatic epiretinal membrane least 3 month prior study enrollment date 6 . BCVA 20/40 bad 7 . CMT least 400 micrometer without cystoid macular edema SDOCT 8 . Prior treatment topical NSAIDs without resolution macular thicken visual acuity improvement 1 . Advanced glaucoma ( cupdisc ratio 0.8 great ) 2 . History glaucoma filter tube shunt implant surgery 3 . Steroid responsive intraocular hypertension 4 . Diabetic retinopathy 5 . History uveitis 6 . Use systemic intraocular corticosteroid 7 . Active suspect ocular periocular infection 8 . Other confound intraocular pathology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>